Beam takes its time to the clinic; Aspen gets clearance to test Parkinson’s cell therapy in humans

Over a year and a half since Beam Therapeutics received clearance from the FDA to test its base-edited sickle cell therapy in humans, it has yet to dose a patient.

But Beam insists that it is getting close — in its second quarter report, Beam updated that it has consented enough patients to fill its first cohort of three patients. Beam said it plans to report data from multiple patients in 2024, though it did not specify when it plans to dose its first patient.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

How health care organizations can set up chief medical officers for success

It should be obvious that medical school and clinical experience, in themselves, can’t fully prepare someone for the C-suite, any more than an MBA and

October 5, 2023

Availity Launches AI-Powered Claims Denial Prediction Tool

What You Should Know: – Availity, a real-time health information network launches Predictive Editing, a revolutionary feature within its Availity Essentials Pro™ platform. – The

April 5, 2024

LincRNA discovery could lead to targeted treatments

Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up

April 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.